Cell-Derived Vesicles for mRNA Delivery

Pharmaceutics. 2022 Dec 2;14(12):2699. doi: 10.3390/pharmaceutics14122699.

Abstract

The clinical translation of messenger mRNA (mRNA)-based therapeutics requires safe and effective delivery systems. Although considerable progress has been made on the development of mRNA delivery systems, many challenges, such as the dose-limiting toxicity and specific delivery to extrahepatic tissues, still remain. Cell-derived vesicles, a type of endogenous membranous particle secreted from living cells, can be leveraged to load mRNA during or after their biogenesis. Currently, they have received increasing interest for mRNA delivery due to their natural origin, good biocompatibility, cell-specific tropism, and unique ability to cross physiological barriers. In this review, we provide an overview of recent advances in the naturally occurring mRNA delivery platforms and their biomedical applications. Furthermore, the future perspectives on clinical translation of cell-derived vesicles have been discussed.

Keywords: cell-derived vesicles; exosome; extracellular vesicles; mRNA delivery; microvesicles.

Publication types

  • Review